Abstract:Introduction: Pulsed field ablation (PFA) exploits the delivery of short high-voltage shocks to induce cells death via irreversible electroporation. The therapy offers a potential paradigm shift for catheter ablation of cardiac arrhythmia. We designed an AC-burst generator and therapeutic strategy, based on the existing knowledge between efficacy and safety among different pulses. We performed a proof-of-concept chronic animal trial to test the feasibility and safety of our method and technology. Methods: We employed 6 female swine - weight 53.75 ± 4.77 kg - in this study. With fluoroscopic and electroanatomical mapping assistance, we performed ECG-gated AC-PFA in the following settings: in the left atrium with a decapolar loop catheter with electrodes connected in bipolar fashion; across the interventricular septum applying energy between the distal electrodes of two tip catheters. After procedure and 4-week follow-up, the animals were euthanized, and the hearts were inspected for tissue changes and characterized. We perform finite element method simulation of our AC-PFA scenarios to corroborate our method and better interpret our findings. Results: We applied square, 50% duty cycle, AC bursts of 100 μs duration, 100 kHz internal frequency, 900 V for 60 pulses in the atrium and 1500 V for 120 pulses in the septum. The inter-burst interval was determined by the native heart rhythm - 69 ± 9 bpm. Acute changes in the atrial and ventricular electrograms were immediately visible at the sites of AC-PFA - signals were elongated and reduced in amplitude (p < 0.0001) and tissue impedance dropped (p = 0.011). No adverse event (e.g., esophageal temperature rises or gas bubble streams) was observed - while twitching was avoided by addition of electrosurgical return electrodes. The implemented numerical simulations confirmed the non-thermal nature of our AC-PFA and provided specific information on the estimated treated area and need of pulse trains. The postmortem chest inspection showed no peripheral damage, but epicardial and endocardial discolorations at sites of ablation. T1-weighted scans revealed specific tissue changes in atria and ventricles, confirmed to be fibrotic scars via trichrome staining. We found isolated, transmural and continuous scars. A surviving cardiomyocyte core was visible in basal ventricular lesions. Conclusion: We proved that our method and technology of AC-PFA is feasible and safe for atrial and ventricular myocardial ablation, supporting their systematic investigation into effectiveness evaluation for the treatment of cardiac arrhythmia. Further optimization, with energy titration or longer follow-up, is required for a robust atrial and ventricular AC-PFA.

Utilizing Human-Induced Pluripotent Stem Cells to Study Cardiac Electroporation Pulsed-Field Ablation

Human in vitro assay for irreversible electroporation cardiac ablation

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Pulsed electric field performance calculator tool based on an in vitro human cardiac model

Pulsed Field Ablation as a Precise Approach for Cardiac Arrhythmia Treatment via Cardiac Microenvironment Remodeling

Establishing electroporation thresholds for targeted cell specific cardiac ablation in a 2D culture model

Toward a Quasi-dynamic Pulsed Field Electroporation Numerical Model for Cardiac Ablation: Predicting Tissue Conductance Changes and Ablation Lesion Patterns

AC Pulsed Field Ablation Is Feasible and Safe in Atrial and Ventricular Settings: A Proof-of-Concept Chronic Animal Study

Pearls and Pitfalls of Pulsed Field Ablation

Advances in the Application of Pulsed Field Ablation for Arrhythmia Treatment

Pulsed Field Ablation: A Promise with Future Broad-based Applicability or a Pause needing Further Analysis

Electroporation Parameters for Human Cardiomyocyte Ablation In Vitro

Process Analysis and Parameter Selection of Cardiomyocyte Electroporation Based on the Finite Element Method

Primer on Pulsed Electrical Field Ablation: Understanding the Benefits and Limitations

Time Course of Irreversible Electroporation Lesion Development Through Short- and Long-Term Follow-Up in Pulsed-Field Ablation–Treated Hearts

State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective

Opportunities and Challenges in Catheter-Based Irreversible Electroporation for Ventricular Tachycardia

Intracardiac pulsed field ablation: Proof of feasibility in a chronic porcine model

Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells

Methods and techniques to optimize energy delivery using the circular array pulsed field ablation catheter

A Preclinical Study of Pulsed Field Ablation of "Difficult" Ventricular Targets: Intracavitary Mobile Structures, Interventricular Septum and Left Ventricular Free Wall